Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Unii-nzw2bow35n
2. 929046-33-3
3. Nt-814
4. Elinzanetant [inn]
5. Elinzanetant [usan]
6. Nzw2bow35n
7. Bay3427080
8. Bay-3427080
9. 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide
10. 2-[3,5-bis(trifluoromethyl)phenyl]-n-{4-(4-fluoro-2-methylphenyl)-6-[(7s,9as)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1h)-yl]-3-pyridinyl}-n,2-dimethylpropanamide
11. Elinzanetant [who-dd]
12. Schembl303180
13. Chembl4802157
14. Dtxsid101337049
15. Ex-a6225
16. Who 10952
17. Hy-109171
18. Cs-0116361
19. 2-[3,5-bis(trifluoromethyl)phenyl]-n-{4-(4-fluoro-2-methylphenyl)-6-[(7s,9as)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1h)-yl]pyridin-3-yl}-n,2-dimethylpropanamide
20. Benzamide, 3-(5-methyl-2-tbenzeneacetamide, N-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.-trimethyl-3,5-bis(trifluoromethyl)-
21. Benzamide, 3-(5-methyl-2-tbenzeneacetamide, N-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,alpha,alpha-trimethyl-3,5-bis(trifluoromethyl)-
22. N-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide
| Molecular Weight | 668.6 g/mol |
|---|---|
| Molecular Formula | C33H35F7N4O3 |
| XLogP3 | 5.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 6 |
| Exact Mass | 668.25973813 g/mol |
| Monoisotopic Mass | 668.25973813 g/mol |
| Topological Polar Surface Area | 69.1 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 1060 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer Submits EU Marketing Application for Menopause Relief Drug
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. Food And Drug Administration (FDA) accepts New Drug Application For elinzanetant
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
OASIS 3 Study Supports Efficacy and Safety of Elinzanetant for Menopause Symptoms
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer to Present Data from Phase III OASIS 3 Study on Elinzanetant for Menopausal Symptoms
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer Submits NDA for Elinzanetant for Menopause Symptoms to U.S. FDA
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Elinzanetant Reduces Hot Flashes In Menopausal Women
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for moderate to severe vasomotor symptoms (VMS, also known as hot flashes.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer To Unveil Phase III Data For Elinzanetant In Treating Menopause-Related Symptoms
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for moderate to severe vasomotor symptoms (VMS, also known as hot flashes.
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 08, 2024
Details:
BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms (known as hot flashes).
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Positive Phase III Results Support Bayer's Marketing Authorization For Elinzanetant
Details : BAY3427080 (elinzanetant) is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is being evaluated for the treatment of moderate to severe vasomotor symptoms (known as hot flashes).
Brand Name : BAY3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 19, 2024
Details:
BAY-3427080 (elinzanetant) is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is in phase 2 clinical development for the treatment of sleep disturbances associated with menopause.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY-3427080
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Results from First Patient in Kiromic’s Deltacel-01 Trial Indicate Tumor Reduction
Details : BAY-3427080 (elinzanetant) is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, which is in phase 2 clinical development for the treatment of sleep disturbances associated with menopause.
Brand Name : BAY-3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
Details:
BAY-3427080 (elinzanetant) is a first dual NK-1,3 receptor antagonist in late-stage clinical development for moderate to severe VMS associated with menopause, administered orally once daily.
Lead Product(s): Elinzanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: BAY-3427080
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Lead Product(s) : Elinzanetant
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bayer’s Elinzanetant Meets Endpoints in OASIS 1 and 2 Phase III Studies
Details : BAY-3427080 (elinzanetant) is a first dual NK-1,3 receptor antagonist in late-stage clinical development for moderate to severe VMS associated with menopause, administered orally once daily.
Brand Name : BAY-3427080
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 08, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
